Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Schepisi

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|March 2, 2023
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell TumorsGiuseppe Schepisi, Caterina Gianni, Maria Concetta Cursano, et al.
Therapeutic Advances in Medical Oncology|March 12, 2021
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imagingVincenza Conteduca, Giulia Poti, Paola Caroli, et al.
Frontiers in Oncology|August 25, 2022
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatmentCaterina Gianni, Michela Palleschi, Giuseppe Schepisi, et al.
Journal for Immunotherapy of Cancer|October 18, 2019
CAR-T cell therapy: a potential new strategy against prostate cancerGiuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, et al.
Expert Review of Anticancer Therapy|December 24, 2024
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancerRiccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, et al.
Oncotarget|May 19, 2016
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancerSamanta Salvi, Valentina Casadio, Vincenza Conteduca, et al.
Molecular Oncology|October 17, 2021
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcomeVincenza Conteduca, Emanuela Scarpi, Paola Caroli, et al.
International Journal of Molecular Sciences|December 6, 2017
Immunotherapy for Prostate Cancer: Where We Are HeadedGiuseppe Schepisi, Alberto Farolfi, Vincenza Conteduca, et al.
International Journal of Molecular Sciences|June 2, 2021
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic ReviewGiuseppe Schepisi, Caterina Gianni, Sara Bleve, et al.
Cancers|March 6, 2021
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell TherapyGiuseppe Schepisi, Chiara Casadei, Ilaria Toma, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|March 2, 2023
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell TumorsGiuseppe Schepisi, Caterina Gianni, Maria Concetta Cursano, et al.
Therapeutic Advances in Medical Oncology|March 12, 2021
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imagingVincenza Conteduca, Giulia Poti, Paola Caroli, et al.
Frontiers in Oncology|August 25, 2022
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatmentCaterina Gianni, Michela Palleschi, Giuseppe Schepisi, et al.
Journal for Immunotherapy of Cancer|October 18, 2019
CAR-T cell therapy: a potential new strategy against prostate cancerGiuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, et al.
Expert Review of Anticancer Therapy|December 24, 2024
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancerRiccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, et al.
Oncotarget|May 19, 2016
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancerSamanta Salvi, Valentina Casadio, Vincenza Conteduca, et al.
Molecular Oncology|October 17, 2021
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcomeVincenza Conteduca, Emanuela Scarpi, Paola Caroli, et al.
International Journal of Molecular Sciences|December 6, 2017
Immunotherapy for Prostate Cancer: Where We Are HeadedGiuseppe Schepisi, Alberto Farolfi, Vincenza Conteduca, et al.
International Journal of Molecular Sciences|June 2, 2021
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic ReviewGiuseppe Schepisi, Caterina Gianni, Sara Bleve, et al.
Cancers|March 6, 2021
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell TherapyGiuseppe Schepisi, Chiara Casadei, Ilaria Toma, et al.
Pageof 7